Xanomeline (3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole) is a muscarinic agonist that is considered to be functionally selective for the M 1 /M 4 receptor subtypes. Part of xanomeline binding is resistant to washing. Wash-resistant xanomeline activates muscarinic receptors persistently, except for the M 5 subtype. Mutation of leucine 6.46 to isoleucine at M 1 or M 4 receptors abolished persistent activation by wash-resistant xanomeline. Reciprocal mutation of isoleucine 6.46 to leucine at the M 5 receptor made it sensitive to activation by wash-resistant xanomeline. Lowering of membrane cholesterol made M 1 and M 4 mutants and M 5 wild type receptors sensitive to activation by wash-resistant xanomeline. Molecular docking revealed a cholesterol binding site in the groove between transmembrane helices 6 and 7. Molecular dynamics showed that interaction of cholesterol with this binding site attenuates receptor activation. We hypothesize that differences in cholesterol binding to this site between muscarinic receptor subtypes may constitute the basis for xanomeline apparent functional selectivity and may have notable therapeutic implications. Differences in receptor-membrane interactions, rather than in agonist-receptor interactions, represent a novel possibility to achieve pharmacological selectivity. Our findings may be applicable to other G protein coupled receptors.
Introduction
Muscarinic acetylcholine receptors are spread throughout the human body including the central and peripheral nervous system and many target organs (Eglen et al., 2012) . They mediate a wide range of physiological functions and are involved in disorders including Alzheimer's disease or schizophrenia (Clader and Wang, 2005; Karam et al., 2010) . Xanomeline (3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole) is a prototypic muscarinic agonist developed with the aim to treat Alzheimer's disease but was withdrawn from clinical studies due to severe side-effects. Its beneficiary effects in enhancing memory in animals are ascribed to preferential activation of M 1 receptors (Bymaster et al., 1998; Martino et al., 2011; Bradley et al., 2016) . However, xanomeline exerts same affinity and efficacy at all five subtypes of muscarinic receptors (Jakubík et al., 2008) . A special feature of xanomeline is its resistance to washing that leads to persistent receptor activation (Christopoulos et al., 1998) . The only difference found in xanomeline action at various subtypes of muscarinic receptors is in its differential efficacy of persistent receptor activation, having highest efficacy at M 1 and M 4 receptors ( Santr u ckov a et al., 2014) . On the other hand, wash-resistant xanomeline causes long-term receptor antagonism at M 5 receptors (Grant and El-Fakahany, 2005) .
Activation of muscarinic receptors involves a relative movement of transmembrane (TM) helices 3 and 6 (Kruse et al., 2013) . Within these two a-helices, M 1 differs from other receptors in twelve positions. The sequence of M 1 and M 4 receptors is similar but different from sequence of M 5 receptor only at two residues (Fig. 1) . These residues at position 6.35 and 6.46 (Ballesteros and Weinstein numbering (Ballesteros et al., 1995) ) are oriented towards the membrane. Cholesterol was found to be co-crystallized with a number of G-protein coupled receptors (Gimpl, 2016) . Hydrophobic residues in position 6.46 of adenosine A2 A and m-opioid receptor were shown to interact with cholesterol in the extracellular leaflet of the cell membrane (Liu et al., 2012; Manglik et al., 2012) . Several lines of evidence suggest that cholesterol regulates the functional response of adenosine as well as opioid receptors (Lasley, 2011; Levitt et al., 2009) .
In the present study, we show that mutation of residues in positions 6.35 and 6.46 in the M 1 muscarinic receptor affect persistent activation by wash-resistant xanomeline. Furthermore, we show that membrane cholesterol prevents persistent activation by washresistant xanomeline and that the inhibitory effect of cholesterol is mediated through interaction with residues in positions 6.35 and 6.46. By applying molecular modelling, we identified a cholesterol binding site in the groove between TM 6 and TM 7 that involves residues 6.35 and 6.46 and found that cholesterol binding to this site prevents receptor activation. We hypothesize that subtype differences in cholesterol binding to this site may constitute the molecular basis for apparent functional selectivity of xanomeline in persistent activation of muscarinic receptors.
Materials and methods

Receptor mutagenesis and generation of cell lines
New stable Chinese hamster ovary (CHO) cells lines expressing individual mutants of M 1 , M 4 or M 5 receptors were prepared. The mammalian expression vector pcDNA3.1 (Invitrogen) containing the coding sequence of the human variants of muscarinic receptors and G 15 G-protein were obtained from Missouri S&T cDNA Resource Center (Rolla, MO, USA). Plasmids coding muscarinic receptors were used to generate sequences with the desired amino acid substitution using Quick Change II Site-directed Mutagenesis Kit (Stratagene). A plasmid containing G 15 G-protein was used to couple M 4 receptors to the phospholipase C signalling cascade. CHO-K1 cells were transfected with desired plasmids using Lipofectamine 3000 (Invitrogen). Subconfluent cells were washed with phosphate-buffered saline and then Opti-MEM (Life Technologies) containing Lipofectamine at a final concentration of 1.5 ml/ml and plasmid DNA was applied at a final concentration of 0.5 mg/ml. After 48 h cells were diluted 1000-times by subculturing and geneticin (Life Technologies) or hygromycin-B (Toku-E) were added at final concentrations of 800 ng/ml and 200 ng/ml, respectively, for selection of transfected clones. Expression of new constructs was checked by reverse transcription quantitative PCR. Mediator RNA was isolated from CHO cell lines using TriPure Isolation Reagent (Roche). Reverse transcription was done using M-MLV Reverse Transcriptase (Promega), Oligo (dT) anchored primers and quantified using LightCycler ® 480 SYBR Green I Master in LightCycler ® 480 Instrument II system (Roche) and analysed by LightCycler ® 480 Software 1.5.0.
Cell culture and membrane preparation
Chinese hamster ovary cells expressing with wild-type (wt) or mutated muscarinic receptors were grown to confluence in 75 cm 2 flasks in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Two million cells were subcultured in 100-mm Petri dishes. The medium was supplemented with 5 mM sodium butyrate for the last 24 h of cultivation to increase receptor expression. Cells were washed with phosphate-buffered saline and manually harvested on day 5 after subculture and centrifuged for 3 min at 250 Â g. The pellet was suspended in 10 ml of ice-cold homogenization medium (100 mM NaCl, 20 mM Na-HEPES, Fig. 1 . Sequences of TM3 and TM6 Aligned sequences of TM3 and TM6 of muscarinic receptors. *, Non-conserved residues; bold, M 1 and M 4 are the same but different from M 5 ; cyan, non-polar; green, polar; turquoise, aromatic polar; magenta, acidic; red, basic amino acids. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 10 mM EDTA, pH ¼ 7.4) and homogenized on ice by two 30 s strokes using a Polytron homogenizer (Ultra-Turrax; Janke & Kunkel GmbH & Co. KG, IKA-Labortechnik, Staufen, Germany) with a 30-sec pause between strokes. Cell homogenates were centrifuged for 5 min at 1000 Â g. The supernatant was collected and centrifuged for 30 min at 30,000 Â g. Pellets were suspended in the incubation medium (100 mM NaCl, 10 mM MgCl 2 , 20 mM Na-HEPES, pH ¼ 7.4), left for 30 min at 4 C, and then centrifuged again for 30 min at 30,000 Â g. Resulting membrane pellets were kept at À80 C until assayed.
Membrane cholesterol
The level of membrane cholesterol was decreased by incubation of whole cells in Krebs-HEPES buffer (KHB; final concentrations in mM: NaCl 138; KCl 4; CaCl 2 1.3; MgCl 2 1; NaH 2 PO 4 1.2; Hepes 20; glucose 10; pH adjusted to 7.4) supplemented with 10 mM methylb-cyclodextrin (MbCD) at 37 C for 30 min. In case of cells attached to 24-mm cover glass for microfluorometry, cells were incubated in 2 ml of KHB supplemented with 10 mM MbCD in 3.5 cm Petri dish. In case of cell suspension for cAMP or inositol phosphates assay, concentration of the cells in suspension was 20 million cells per ml. After incubation, medium was removed and cells were washed twice with triple of incubation volume of fresh KHB. To test reversibility of effects of reduced level of membrane cholesterol, cells with reduced membrane cholesterol level (MbCD treated) were incubated in KHB supplemented with 2 mM cholesterol saturated MbCD at 37 C for 1 h. After incubation, medium was removed and cells were washed twice with the triple of incubation volume of fresh KHB.
Treatment with xanomeline
To determine effects of xanomeline resistant to washing, cells or membranes were either sham treated or treated with 10 mM xanomeline prior to experiments as follows. Cells were exposed to xanomeline for 20 min at 37 C. In case of cells attached to 24-mm cover glass for microfluorometry, cells were incubated in 2 ml of KHB in 3.5 cm Petri dish. In case of cell suspension for cAMP or inositol phosphates assay, concentration of the cells in suspension was 20 million cells per ml. Then cells were washed 3-times with triple volume of fresh KHB. Then cells were resuspended in triple volume of fresh KHB and incubated for 1 h at 37 C. Finally, cells were washed 3-times with triple volume of fresh KHB. For binding experiments, membranes were resuspended in incubation buffer (1 mg of proteins per ml) supplemented with xanomeline in final concentrations ranging from 100 nM to 0.1 mM and incubated for 20 min at 37 C. Then membranes were washed 3-times in 10-fold volume of incubation buffer by recentrifugation and resuspension (30 min at 30,000 g). Membranes were then resuspended in 10-fold volume of incubation buffer, incubated for 1 h, and again washed 3-times by recentrifugation.
Radioligand binding experiments
Membranes (20e50 mg of membrane proteins per sample) were incubated in 96-well plates for 3 h (M 1 , M 4 ) to 5 h (M 5 ) at 30 C in 400 ml of incubation medium. Whatman GF/C glass fibre filters (Whatman) using a Brandel harvester (Brandel, USA). Filters were dried in a microwave oven (3 min, 800 W) and then solid scintillator Meltilex A was melted on filters (105 C, 60 s) using a hot plate. The filters were cooled and counted in a Wallac Microbeta scintillation counter (Wallac, Finland).
Accumulation of inositol phosphates (IP X )
Accumulation of inositol phosphates (IP X ) was assayed in cells in suspension. IP X was determined after separation on ion-exchange columns (Dowex 1X8-200, Sigma, USA). Cells were harvested by mild trypsinization and resuspended in KHB. First, cells were treated with xanomeline or sham treated: Cells were incubated for 20 min at 37 C with xanomeline, washed 3 times with KHB, incubated in excess of KHB for 1 h at 37 C and then washed 3 times with KHB. Treated cells were resuspended in KHB supplemented with 500 nM [ 3 H]myo-inositol (ARC, USA) and incubated at 37 C for 1 h. Then they were washed once with excess of KHB, resuspended in KHB containing 10 mM LiCl, and incubated for 1 h at 37 C in the presence of indicated concentrations of agonists. Incubation was terminated by the addition of 0.5 ml of stopping solution (chloroform: methanol: HCl; 2: 1: 0.1) and placed on ice for 20 min. An aliquot (0.65 ml) of the upper (aqueous) phase was taken and loaded onto ion-exchange columns. Columns were washed with 10 ml of deionized water and 20 ml of 60 mM ammonium formate/5 mM sodium borate solution. IP X were collectively eluted from columns by 4 ml of 1 M ammonium formate-0.1 M/formic acid buffer.
Microfluorometry of free intracellular calcium
Cells grown on glass coverslips were washed twice with KHB and then pre-labeled with 5 mM Fura 2-AM in KHB enriched with 1 mM pluronic P68 for 1 h at 37 C. After pre-labeling cells were washed twice with KHB, mounted to a superfusion chamber, placed on a stage of Olympus IX-90 inverted fluorescent microscope, and continuously superfused at a flow rate 0.5 ml/min. Microfluorometry was set-up to measure kinetics of the functional response to agonists and to observe the formation of sustained activation by xanomeline. Cells expressing wt or mutant muscarinic receptors were exposed for 10 s (time for best response without desensitization) to carbachol or 40 s (shortest time to get sustained activation) to xanomeline. Cells were exposed to agonist for up to 4 times. Individual exposures were separated by 5e10 min superfusion with agonist-free KHB medium. Images were recorded using a CCD camera connected to a computer equipped with Metafluor 7.0 software (Visitron Systems GmBH, Germany) for image acquisition and analysis. Images of the whole measured field containing about 40 cells were saved and analysed off-line after the measurements. Two pairs of images per second were recorded. Only responding cells were selected (by exclusion of weakly and/or slow responding cells or cells with abnormal response; the outliers in peak value, time to peak or fall time were identified by interquartile range (IQR) where data below Q1-1.5*IQR and above Q3þ1.5*IQR were considered outliers) for further analysis. Calcium signals of selected cells were averaged, normalized to basal calcium level and further analysed by means of array-oriented program Grace (http:// plasma-gate.weizmann.ac.il/Grace).
Data analysis
Data from experiments were processed in Libre Office and then analysed and plotted using program Grace (http://plasma-gate. weizmann.ac.il/Grace). Statistical analysis was performed using statistical package R (http://www.R-project.org). For non-linear regression analysis, the following equations were used:
where y is specific binding at free concentration x, B MAX is maximum binding capacity, and K D is equilibrium dissociation constant.
Competition binding
where y is specific radioligand binding at concentration x of competitor expressed as percent of binding in the absence of competitor, IC 50 is concentration causing 50% inhibition of radioligand binding at high (IC 50high ) and low (IC 50low ) affinity binding sites, f low is fraction of low-affinity binding sites expressed in percents. Inhibition constant K I was calculated as:
where [D] is concentration of radioligand used and K D is its equilibrium dissociation constant.
Concentration response curve
Following Eq. (4a) was fitted to concentration response of inositol phosphates level to agonists.
where y is response normalized to basal activity at concentration x, E MAX is maximal effect, EC 50 is concentration causing half-maximal effect, and nH is Hill coefficient. Eq. (4b) was fitted to concentration response of cAMP that was U-shaped.
After treatment with MbCD concentration response curves of cAMP level became steep and slope factor had to be introduced.
To compare efficacies at receptors with different expression level the apparent affinity constant K G of the G protein for the agonist-receptor complex was calculated according to Lu and Hulme (1999) using the following equation:
where E MAX FR is maximal response calculated according to Eq. (4) and expressed as a fraction of E MAX of carbachol (E MAX agonist e 1)/ (E MAX carbachol e 1) at CHO cells with high expression, and B MAX is maximum binding capacity of cell membranes calculated according to Eq. (1).
2.9. Molecular modelling 2.9.1. Preparation of receptors Model of the M 1 receptor in an inactive state was based on the crystal structure 5CXV (Thal et al., 2016) . Non-protein molecules and hydrolase part of protein were deleted, and resulting receptor protein was processed in Maestro using Protein Preparation Wizard according to Sastry et al. guidelines (Sastry et al., 2013) . Mutation L376I in M 1 receptor was made using FoldX plug-in in YASARA (Van Durme et al., 2011) . M 1 receptor in active conformation was made by morphing of M 1 in an inactive conformation (5CXV) to an active conformation of M 2 receptor (4MQS) (Kruse et al., 2013) using YASARA (Krieger et al., 2004) . First tiotropium molecule was replaced with iperoxo in starting structure (5CVX) and nonconserved residues were removed from target structure (4MQS). Then structure of M 1 receptor was morphed by application of 50 pN force at 20 steps.
Xanomeline docking
Docking of xanomeline was done using Schrodinger Software Suit (Schr€ odinger LLC, New York, NY) with procedure described earlier . The structure of xanomeline was downloaded from PubChem database (http://pubchem.ncbi.nlm. nih.gov) and prepared for docking in Maestro using LigPrep. Xanomeline was docked to the receptor using Induced Fit Docking procedure. Tiotropium was set to define the binding site. Initial Glide docking step was set to "Standard Precision" without explicit constraints. In Prime refinement step, amino acid residues within 5 Å form ligand were refined in single pass. Glide re-docking step was set to "Extra Precision". Top 20 poses were then re-evaluated using Prime MM-GB/SA. The highest pose possessing both hydrogen bond to Asn 382 and Asp 105 was selected for further work.
Cholesterol docking
The structure of cholesterol was downloaded from PubChem database (pubchem.ncbi.nlm.nih.gov) and was docked to the xanomeline-M 1 receptor complex either in the wild-type or mutant form. Docking was done using YASARA implementation of AutoDock. The binding site was defined as 5 Å extension in all directions to residues 365 and 376 and AutoDock local search method was employed (Trott and Olson, 2010) .
Simulation of molecular dynamics
To evaluate cholesterol binding to the receptor, conventional molecular dynamics (MD) was simulated using Desmond/GPU ver. 4.5. The simulated system consisted of receptor-ligand complex in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) membrane set to receptor helices in water and 0.15 NaCl. The system was first relaxed by the standard Desmond protocol for membrane proteins and then 1.2 ns NPT (Noose-Hover chain thermostat at 300 K, Martyna-Tobias-Klein barostat at 1.01325 bar, isotropic coupling, Coulombic cutoff at 0.9 nm) followed by 120 ns NVE molecular dynamics without restrains was simulated. MD was run 3-times with various initial velocities. In Maestro the quality of molecular dynamics simulation was assessed by Simulation Quality Analysis tools, analysed by Simulation Event Analysis tool and ligand-receptor interactions were identified using Simulation Interaction Diagram tool.
To model receptor activation, accelerated MD was simulated by NAMD (Phillips et al., 2005) implementing procedure of Miao et al. (2013) . After standard procedure for membrane systems consisting of energy minimization, membrane relaxation and system equilibration, 100 ns of conventional MD was run that was followed by 500 ns of accelerated MD. For control, accelerated MD was run also for M 1 receptor in an inactive conformation stabilised by tiotropium (5CXV) and in an active conformation stabilised by iperoxo.
Results
Design of mutants
The M 1 and M 4 receptors markedly differ from the M 5 receptor in regard to activation by wash-resistant xanomeline. Since the principal change in conformation upon receptor activation involves relative movement of the third and the sixth transmembrane ahelices (TM 3 and TM 6), sequences in these regions were searched for differences among muscarinic receptor subtypes (Fig. 1) . Sequences within TM 3 vary in two positions (3.35 and 3.45; Ballesteros and Weinstein numbering (Ballesteros et al., 1995) ), marked by stars in Fig. 1, top) . The M 1 receptor differs from the M 4 subtype at both positions. Within TM 6 (Fig. 1, bottom Fig. SI1 ).
Accumulation of inositol phosphates and cAMP
The functional response to agonists was determined as an increase in accumulation of inositol phosphates (M 1 and M 5 receptors) or as an inhibition of forskolin-stimulated synthesis of cAMP (M 4 receptors) ( Table 2 , Fig. 2 ). Both carbachol and xanomeline activated mutant M 1 receptors with lower potency than wt receptors (Table 2) . Maximal stimulation by carbachol was the same at mutant and wt receptors but the efficacy of xanomeline was lower at the R365Q and L376I mutants (K G 1.4 ± 0.2 and 0.38 ± 0.4, respectively, vs. 3.7 ± 0.4; K G according to Eq. (5)). Wash resistant xanomeline stimulated the M 1 R365Q mutant with a lower potency and efficacy (K G 0.22 ± 0.03 vs. 3.7 ± 0.4) than the M 1 wt. At the M 1 L376I mutant wash-resistant xanomeline produced no response. Cells expressing M 4 L411I had higher expression level (Table 1 ) and lower basal level of cAMP (Fig. 3) than cells expressing M 4 wt. This suggests M 4 receptors may be constitutively active and greater expression of the mutant receptor results in greater inhibition of cAMP under basal conditions. Mutation L411I of the M 4 receptor led to a decrease in efficacy without a change in potency of carbachol and decreased both the efficacy and potency of xanomeline when it was present throughout the stimulation period. However, this mutation resulted in complete obliteration of the response to washresistant xanomeline.
Mutation I453L of the M 5 receptor decreased the potency of carbachol without a change in efficacy and increased both the potency and efficacy of the reversible component of xanomeline action. While the M 5 wt receptor showed no response to washresistant xanomeline, M 5 I453L showed a response to cells preincubated with xanomeline followed by washing with similar potency to that of wash-resistant xanomeline at the M 1 wt. Moreover, the efficacy of xanomeline wash-resistant binding was similar to that of the reversible component of xanomeline binding at the M 5 wt receptor.
Next, we investigated the effects of exposure of cells to 10 mM xanomeline for 20 min, followed by washing, on the response to carbachol (Fig. 3, Supplementary information Table SI1 ). Exposure to xanomeline led to an increase in the basal level of inositol phosphates in cells expressing M 1 wt and a decrease in basal levels of cAMP in cells expressing M 4 wt receptors, confirming persistent receptor activation by xanomeline. Basal levels of inositol phosphates in cells expressing the M 5 wt receptor were not changed, indicating the absence of persistent activation by xanomeline. In contrast, exposure to xanomeline did not change the basal levels of second messengers (inositol phosphates, cAMP) at M 1 L376I and M 4 L411I but increased it at the inverse mutant M 5 I453L. Taken together, these mutations reversed the properties of their respective wild types. Exposure to xanomeline decreased the potency of carbachol at all wt and mutant receptors to a similar extent (about 10-times) confirming wash-resistant binding of xanomeline. 
Measurement of intracellular calcium
M 4 wt and mutant receptors were artificially coupled to the phospholipase C pathway by co-transfection with the G 15 G-protein. Changes in the level of free intracellular calcium upon stimulation by carbachol or xanomeline were measured in microfluorometric experiments. Stimulation of cells expressing wt or mutant receptors by carbachol for 10 s led to a transient increase in the level of intracellular Ca 2þ (Fig. 4 , graphs in the left and middle columns). Peak change in the level of intracellular Ca 2þ was concentration dependent and showed similar potency at each mutant and the respective wt receptor (Fig. 4 , graphs in the right column, Supplementary information Table SI2 ). Time to peak was not changed by mutations, indicating no modification of receptor activation kinetics. At M 1 and M 5 receptors, carbachol potency to release intracellular calcium is higher than its potency to increase the level of inositol phosphates, indicating signal amplification. Stimulation of cells expressing wt or mutant receptors by xanomeline for 40 s led to a transient increase in the level of intracellular Ca 2þ (Fig. 5 , graphs in left and middle columns). The potency of xanomeline was similar for each mutant and the respective wt receptor (Fig. 5 , graphs in the right column, circles, Supplementary information Table SI2 ). Similar to carbachol, time to peak was not changed by mutations, confirming no change in receptor activation kinetics. However, the level of intracellular Ca 2þ did not return back to that prior to stimulation at M 1 wt, M 4 wt and M 5 I453L mutant receptors upon termination of exposure to xanomeline. This reflects the persistent receptor activation by wash-resistant xanomeline. The magnitude of the residual signal (time 300e310 s) at these receptors was concentration dependent (Fig. 5 , graphs in the right column, squares). The residual signal was strongly decreased at M 1 L376I and M 4 L411I mutants indicating that these mutations abolish persistent receptor activation by xanomeline, even though binding studies indicated the presence of xanomeline wash-resistant binding at these receptors. Unlike carbachol at M 1 and M 5 receptors, xanomeline potency to release intracellular calcium is similar to its potency to increase the level of inositol phosphates.
Molecular modelling
The targeted mutated residues (L376 and R365 of the M 1 receptor) are oriented towards the membrane. The distance between them is about 2.1 nm, which is similar to the length of cholesterol. This suggests possible cholesterol binding to this part of the receptor. Docking of cholesterol to the intracellular half of TM 6 of the M 1 receptor at an inactive conformation in the complex with xanomeline (see Methods, section 2.9.3.) by Glade resulted in many poses that scored equally. Docking by the YASARA implementation of AutoDock, on the other hand, resulted in only two clusters of binding poses. Docking of cholesterol to the un-liganded receptor gave the same docking poses (data not shown). Both top poses interacted by a hydrogen bond with R365 and the pose closer to TM 7 also interacted with L376 (Fig. 6, left) . Estimated binding energies of the pose closer to TM 5 and TM 7 were 4.7 and 5.6 kcal/mol, respectively. At a model of the L376I mutant receptor, both top poses interacted by hydrogen bonding with R365 and the pose closer to TM 7 also interacted with I376 (Fig. 6, right) . Estimated binding energies of 4.6 and 5.5 kcal/mol for poses closer to TM 5 and TM 7, respectively, were the same as estimated binding energies to the wt receptor. In comparison with L376 in wt, I376 in the mutant receptor is rotated towards the molecule of cholesterol bound between TM 6 and TM 7.
Next, a system consisting of the receptor in membrane and NaCl water solution was constructed and molecular dynamics (MD) were simulated to investigate the stability of cholesterol binding. During the first 20 ns of MD the molecule of cholesterol closer to TM 5 dissociated from the receptor and only occasionally (in less than 25% time frames) interacted with S368 via a hydrogen bond. The second molecule of cholesterol, closer to TM 7, remained bound to wt as well as L376I mutant receptor during the entire period of 120 ns MD (Supplementary Videos 1 and 2). Analysis of interactions over the MD trajectory has shown that the cholesterol molecule closer to TM 7 interacts with R365 via polar interactions (hydrogen bonds, ionic and water bridges) and with L376 via hydrophobic interactions (Fig. 7, left) . A similar set of interactions was found at MD of L376I mutants (Fig. 7, right) . The hydrophobic interaction of cholesterol with I376 in the mutant receptor was almost 4-times more frequent than with L376 in the wt receptor. The frequency of hydrogen bonding of cholesterol to R365 almost doubled in comparison with wt. On the other hand, the frequency of hydrophobic interaction of cholesterol with A369 at the mutant receptor was less than half of wt. Cholesterol binds closer to TM 6 at the L376I mutant as documented by interaction at the intracellular edge of TM 6 (water bridges to K361, hydrophobic interactions with A364) that does not occur at wt and absence of interaction with residues at the intracellular edge of TM 7 (water bridges to M416, hydrogen bonds and water bridges to C417) that are present at wt. Taken together, the single mutation L376I changes binding of cholesterol to the groove between TM 6 and TM 7 of the muscarinic receptor.
Supplementary video related to this article can be found at https://doi.org/10.1016/j.neuropharm.2018.01.027.
Accelerated MD (aMD) of the M 1 receptor was simulated to (Table SI2 ). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
investigate possible effects of cholesterol on the activation of receptor in silico (see Methods, section 2.7.4.). For control, we ran aMD of M 1 in the inactive conformation stabilised by the receptor antagonist tiotropium and M 1 receptor in the active conformation stabilised by the antagonist iperoxo. In an inactive conformation, R123 and E360 formed an ionic bond between TM 3 and TM 6. In an active conformation, the ionic lock was absent and the distance between R123 and E360 was greater than in the inactive conformation (Fig. 8) . Further, TM 6 showed an increase in fluctuations of an active conformation. Control run of aMD of the xanomeline-M 1 receptor complex in the inactive conformation showed that xanomeline binding destabilises the ionic lock and partially activates M 1 receptor (Fig. 9 , top) already during conventional MD. Xanomeline fully activated the receptor within 400 ns of aMD. The receptor remained in the active conformation for the rest of 1-ms aMD simulation. Simulation of aMD of the xanomeline-M 1 receptor complex with two molecules of cholesterol bound to TM 6 (Fig. 9 , bottom) showed tighter packing of TM 3 and TM 6 than in the absence of cholesterol. The molecule of cholesterol bound in the groove between TM 5 and TM 6 of the receptor dissociated during aMD. In contrast, the molecule of cholesterol bound in the groove between TM 6 and TM 7 remained bound to the receptor during the entire course of aMD. The receptor remained in an inactive conformation for about half of 1-ms aMD and was only partially active during the second half of aMD. Taken together, in silico experiments demonstrated that cholesterol bound to the groove between TM 6 and TM 7 in the intracellular leaflet of the membrane slowed down receptor activation. 
Effects of cholesterol on receptor binding properties
To test a possible role of cholesterol in persistent receptor activation by xanomeline suggested by molecular modelling, the content of cholesterol in the membrane was decreased from 218 ± 25 to 83 ± 12 nmol/mg of protein by treatment of cells with 10 mM methyl-b-cyclodextrin (MbCD) for 30 min. This treatment had no effect on affinity of [ 3 H]NMS, carbachol nor xanomeline, except about two-fold increase in apparent affinity of wash-resistant xanomeline at M 1 L376I and M 4 L411I mutants (Table 3) .
Cholesterol depletion also led to about 15% increase in the number of biding sites at all receptor subtypes.
Effects of cholesterol on functional response
Cholesterol depletion made analysis of cAMP response unfeasible due to pleiotropy of effects on cAMP signalling. Depletion of membrane cholesterol led to an increase in basal activity of adenylyl cyclase. It also resulted in an increase in potency and efficacy of signalling via G i/o as well as G S G-proteins (Supplementary Information, Fig. SI2 , Table SI4 ). Importantly, L411I mutant M 4 receptor expressing cells became responsive to wash-resistant xanomeline after cholesterol depletion. The steep decrease in cAMP level was followed by a very steep increase. Eq. (4b) did not fit the data ( Supplementary Information, Fig. SI2 , dotted lines) and a slope factor had to be introduced (Eq. (4c) ). The effect of cholesterol depletion on potency of G s signalling was greater (3-fold increase for carbachol and 7-fold increase for xanomeline) than on potency of G i/o signalling (about 2-fold increase for both agonists). Effects of cholesterol depletion on potency of agonists at wt and L411I mutant M 4 receptors were the same. The potency of G S signalling became so close to potency of G i/o signalling that it was impossible to tell apart changes in G i/o and G S efficacies (Supplementary Information, Table SI4 ). Therefore, effects of cholesterol depletion at M 4 wt and mutant receptors were also investigated by measurement of accumulation of inositol phosphates that was easier to analyse and basal level of inositol phospahtes was only slightly increased. M 4 wt and mutant receptors were connected to the phospholipase C pathway by co-transfection with the G 15 G-protein. Treatment with MbCD caused an increase in the basal level of inositol phosphates by 28 ± 2% at M 1 , 8 ± 1% at M 4 and 5 ± 1% at M 5 receptors (Figs. 10  and 11 ). There were marginal effects of MbCD treatment on the response to stimulation by carbachol (Fig. 10 , Table 4 column-wise comparison). In contrast, the potency and maximal response to both acute and wash-resistant xanomeline were increased (Fig. 11 , Tables 5 and 6 ). Importantly, reduction of membrane cholesterol revealed a response to wash-resistant xanomeline at M 1 L376I, M 4 L411I and M 5 wt receptors, suggesting that cholesterol dampens activation by wash-resistant xanomeline at these receptors.
To test the reversibility of effects of lowering cholesterol on receptor activation, MbCD treated cells were replenished with cholesterol by incubation with 2 mM cholesterol saturated MbCD of membrane cholesterol or with replenished cholesterol after initial reduction (hatched symbols) to the immediate effects of xanomeline (circles) or to washresistant xanomeline (squares, after 1 h exposure to xanomeline followed by washing) is expressed as per cent of incorporated radioactivity (ordinate). Data are means ± SD from 3 independent experiments performed in triplicates. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) stopped responding completely to wash-resistant xanomeline after replenishment of cholesterol.
Similar effects of MbCD treatment were observed in preparations from striatum and ventral tegmental area (VTA) (Supplementary Information Fig. SI3 ). Cells freshly prepared form rat striatum and VTA did not respond to 10 mM wash-resistant xanomeline. However, treatment with 10 mM xanomeline increased the level of inositol phosphates at striatal and VTA cells pretreated with 10 mM MbCD by about 10 and 5%, respectively, (Supplementary information Fig. SI3 ).
Discussion
The major findings of this study are i) membrane cholesterol suppresses activation of muscarinic acetylcholine receptors by wash-resistant xanomeline; ii) this effect is due to an interaction of cholesterol with amino acids in the TM 6 at positions 6.35 and 6.45 (Ballesteros and Weinstein numbering (Ballesteros et al., 1995) ); iii) sensitivity to suppression of receptor activation by cholesterol differs among subtypes.
Xanomeline is a drug initially developed for the treatment of Alzheimer's disease (AD) but subsequently retracted from clinical studies due to severe side effects. In long-term in vivo experiments, it had beneficial effects that are attributed to activation of M 1 receptors (Bymaster et al., 1998) . Xanomeline was also suggested for the treatment of schizophrenia (Shekhar et al., 2008) . In this case, preferential activation of M 4 receptors by xanomeline was thought to be involved. However, xanomeline binds to all muscarinic receptor subtypes with the same affinity and activates them with the same potency (Jakubík et al., 2008) . Part of xanomeline binding and activation of muscarinic receptors is persistent (resistant to washing) (Christopoulos et al., 1998; Jakubík et al., 2002) . In a recent study, we have detected subtle differences in the efficacy of activation by xanomeline at M 1 and M 4 receptors on the one hand and M 5 receptors on the other hand ( Santr u ckov a et al., 2014). Moreover, xanomeline activates M 5 receptors only transiently and its persistent binding to this receptor subtype is associated with long-term antagonism, rather than activation (Grant and ElFakahany, 2005) .
A molecular hallmark of activation of muscarinic receptors is a relative movement of TM 3 and TM 6 (Kruse et al., 2013) . Out of these two a-helices, the primary sequence of M 1 resembles M 4 receptor to isoleucine found in the M 5 receptor abolished their activation by wash-resistant xanomeline ( Table 2 ). The affinity of xanomeline wash-resistant binding decreased by only two-fold (Table 1) . Receptor activation by carbachol (assessed by changes in intracellular calcium level) was not affected (Fig. 4) . Although the dampening effect of the L376I mutation at the M 1 receptor on the maximal functional response may in part be due to a lower expression level of the mutant, this is not the case for the L411I mutation at the M 4 receptor, where the expression of the mutant is actually higher than the expression of wt. Conversely to the M 1 and M 4 receptors, the reciprocal mutation of I 6.46 in the M 5 receptor made it sensitive to stimulation by wash-resistant xanomeline. Importantly, this finding is consistent among several assays: accumulation of inositol phosphates (IP X ), inhibition of forskolinstimulated production of cAMP (Table 2 , Figs. 2 and 3) , and measurement of intracellular calcium level (Fig. 5) . In addition, mutation R365Q at the M 1 receptor decreased the potency and efficacy of wash-resistant xanomeline to persistently activate the receptor (Table 2 , Fig. 2 ). Residues at positions 6.35 and 6.46 are oriented outward of the receptor core. Functional oligomerization was postulated for many aminergic GPCRs (Milligan, 2013) , including M 1 muscarinic receptors (Pediani et al., 2016) . TM 6 was found to be part of the dimerization interface of m-opioid receptors (Manglik et al., 2012) .
However, mutations in TM 6, including I6.46 had no effect on dimerization of M 3 muscarinic receptors (McMillin et al., 2011) . Suggested arrangements of dimers of muscarinic receptors do not involve TM 6 in receptor-receptor interface (McMillin et al., 2011; Liste et al., 2015) . Thus, the possibility that mutations at positions 6.35 and 6.46 directly affect receptor dimerization is unlikely.
Evidence for cholesterol interaction with G-protein coupled receptors (GPCRs) is increasing. In fact, cholesterol was found to cocrystallize with a number of GPCRs (Gimpl, 2016) . In the structures of the adenosine A2a receptor (4EIY), m-opioid receptor (4DKL, 5C1M) and viral receptor US28 (4XT1) cholesterol at extracellular leaflet was found to interact with the amino acid at position 6.46. Membrane cholesterol has been shown to regulate the functional response of adenosine or opioid receptors (Lasley, 2011; Levitt et al., 2009 ) and stabilize an inactive conformation of rhodopsin or b2-adrenergic receptors (Oates and Watts, 2011; Gater et al., 2014) . Mutation of L 6.46 in the M 1 and M 4 receptors abolished persistent activation by wash-resistant xanomeline. However, the other amino acid found to play a role in this process, R 6.35 , is situated at the intracellular edge. The distance between side-chains of R365 and L376 is about 2.1 nm, which is similar to the length of the cholesterol molecule. This suggests another possible binding site for cholesterol not yet observed in receptor crystal structures. Indeed, molecular docking revealed two potential binding sites for cholesterol in the vicinity of the intracellular half of TM 6, from which cholesterol may interact via a hydrogen bond with R 6.35 and hydrophobic interactions with L 6.46 (Fig. 6) . Simulation of molecular dynamics (MD) confirmed the stability of cholesterol binding to the groove between TM 7 and TM 6 (Fig. 7 , Supplementary Videos 1 and 2). Moreover, these simulations showed that the single L376I mutation affects cholesterol binding in several ways. Importantly, changes in cholesterol binding include an increase in hydrogen bonding to R365. In the simulation of accelerated MD (aMD) cholesterol bound to the groove between TM 6 and TM 7 suppressed receptor activation (Fig. 9) . This is compatible with the observation that lowering the level of membrane cholesterol leads to the establishment of persistent activation by wash-resistant xanomeline at receptors not originally responding to it (M 1 L376I, M 4 L433I, M 5 wt) and increases the persistent response to xanomeline at the rest of tested receptors (Fig. 11) . Namely, after lowering membrane cholesterol, cells that had not responded to wash-resistant xanomeline (M 1 L376I, M 4 L411I and M 5 wt) showed a response (Fig. 11, open  symbols) . This implies that membrane cholesterol interferes with persistent activation by wash-resistant xanomeline and that its action is mediated by interaction with I 6.46 . Effects of cholesterol on binding properties of xanomeline were marginal (Table 1 vs. Table 3 ) that means that cholesterol affects primarily xanomeline efficacy, e.g. receptor activation. Cholesterol has many divergent effects on signalling via muscarinic receptors (Berstein et al., 1989; Colozo et al., 2007; Michal et al., 2009 Michal et al., , 2014 . Besides affecting membrane fluidity, cholesterol may interact with membrane components including signalling effectors (Head et al., 2014) . Specific to muscarinic receptors, it has been postulated that membrane cholesterol may affect G-protein/effector protein interaction as well as ligand-activated receptor/G-protein interaction (Michal et al., 2014 ). In the current experimental set-up, the marginal changes in accumulation of inositol phosphates in response to stimulation by carbachol upon lowering membrane cholesterol ( Fig. 10 and Table 4 ) excludes the possibility that the observed changes in response to stimulation by wash-resistant xanomeline are mainly effects on post-receptor effector systems. Importantly, all effects of the lowered level of membrane cholesterol were reversed by replenishment of membrane cholesterol ( Fig. 11 hatched versus open symbols and Tables 5 and 6) indicating that the observed changes in the response to xanomeline are indeed a consequence of cholesterol depletion rather than a side-effect of MbCD treatment per se. Similar effects of MbCD treatment were observed in cell preparations from the striatum and ventral tegmental area (VTA) (Supplementary information Fig. SI2 ) indicating that cholesterol also inhibits signalling of wash-resistant xanomeline in native cells. It should be noted, however, that the striatum and VTA express subtypes of muscarinic receptors other than M 5 (Eglen et al., 2012) . At M 4 receptors, depletion of membrane cholesterol resulted in increase in potency and efficacy of both carbachol and xanomeline for both G i/o and G s signalling (Supplemenraty Information Fig. SI2 and Table SI4 ). The increase in potency for G s signalling was greater than increase in potency for G i/o signalling. This may be explained by a necessity of greater outward tilt of TM 6 for G s coupling (Rose et al., 2014) that is prevented by bound membrane cholesterol. In accordance with our observations, it has been shown by simulation of MD of b 2 -adrenergic receptors in silico that cholesterol slows down receptor dynamics and limits conformational variability (Manna et al., 2016) . Experimentally, stabilization of the receptor in an inactive conformation by cholesterol was observed at b 2 -adrenergic and rhodopsin receptors (Oates and Watts, 2011; Gater et al., 2014) . In view of these findings, suppression of receptor activation by cholesterol may be a general phenomenon among class A GPCRs. Despite non-selectivity of xanomeline upon short-term exposure, its functional selectivity was observed in long-term experiments, e.g. as long-term increase in level of inositol phosphates, as analgesic effects at chronic and inflammatory pain or as slow-down of prion neurodegeneration (Bymaster et al., 1998; Martino et al., 2011; Bradley et al., 2016) . Differential sensitivity of individual subtypes of muscarinic receptors to cholesterol inhibition of persistent activation by xanomeline may underlie the molecular basis for the functional selectivity of xanomeline in these long-term experiments. According to our knowledge, this is the first demonstration of pharmacological selectivity due to differences in receptor-membrane interactions at any GPCR. This selectivity is unlikely to be due to different molecular mechanisms of receptor activation, since these mechanisms appear to be conserved among various agonists (Rand akov a et al., 2015) . Still, several possibilities for differential sensitivity to response inhibition by cholesterol may exist. The simplest and most probable cause would be different affinity of receptor subtypes for binding cholesterol. Alternatively, receptor subtypes may differ in sorting to cholesterol-rich versus cholesterol-lean membrane domains or in their quaternary arrangement. Cholesterol-mediated receptor oligomerization via the TM 6-TM 7 interface was modelled for dimers of M 3 muscarinic receptors (Liste et al., 2015) . It is possible that receptor subtypes differ in the degree of oligomerization, which will in turn influence the magnitude of the effect of cholesterol on receptor activation. This receptor subtype-selective modulation of receptor sensitivity works in concert with cholesterol binding to the groove between TM 6 and TM 7 to dampen activation of all muscarinic receptor subtypes. In other words, cholesterol has a more significant effect on activation of the muscarinic receptor subtypes where cholesterol both binds to this groove as well as modulates receptor oligomerization.
Cholinomimetics are used to treat various dementias, including AD, and other disorders affecting cholinergic neurotransmission (Doggrell and Evans, 2003) . Similarly to xanomeline, their efficacy may be negatively affected by cholesterol, whose level increases with age (Lewington et al., 2007) . Moreover, based on genetic, epidemiological and biochemical data cholesterol was identified as a risk factor in the pathogenesis of AD (Puglielli et al., 2003) . Thus, medications that lower blood and membrane cholesterol may have synergistic effects with a cholinomimetic treatment of these disorders. Alternatively, medications that decrease binding of cholesterol to muscarinic receptors may be developed towards the same goal.
Conclusions
Membrane cholesterol suppresses persistent activation of muscarinic receptors by wash-resistant xanomeline. Its effects on persistent activation are mediated by residues in TM 6 at position 6.35 and 6.46. Differential sensitivity of individual receptor subtypes to suppression of receptor activation by cholesterol may underlie the molecular basis for the functional selectivity of xanomeline. The possibility to achieve pharmacological selectivity based on receptor-membrane interactions changes our view on the molecular basis of pharmacological selectivity. These findings may be common for class A GPCRs and have therapeutic potential.
